NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early

(Brigham and Women's Hospital) A year ago, investigators set out to study whether symptomatic COVID-19 outpatients should be given anticoagulant or antiplatelet therapy to prevent clots that were reported among some patients with COVID-19. The data collected to date, through a randomized, double-blinded, placebo-controlled trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), suggests a very low rate of thrombotic complications in the patients studied.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news